| Literature DB >> 26382908 |
Abstract
Minocycline belongs to the family of tetracyclines, which are drugs traditionally approved as antibiotics. Based on preclinical animal cardiac models and clinical neurology trials, this drug has gained special attention as a promising cardiovascular therapeutic agent given its anti-inflammatory, antiapoptotic, antioxidant, and antienzymatic properties. This review focuses on the available evidence for minocycline as a cardioprotective drug, with special attention to mechanisms of action. Ongoing cardiovascular clinical trials are briefly discussed.Entities:
Keywords: apoptose; apoptosis; cardio-protection; cardioprotection; ischemia; ischémie; lésion de reperfusion; minocycline; oxidative stress; reperfusion injury; stress oxydatif
Mesh:
Substances:
Year: 2015 PMID: 26382908 DOI: 10.1139/cjpp-2014-0493
Source DB: PubMed Journal: Can J Physiol Pharmacol ISSN: 0008-4212 Impact factor: 2.273